Drug Profile

VAL 201

Alternative Names: VAL-201

Latest Information Update: 18 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cancer Research Technology
Developer ValiRx
Class Antineoplastics; Peptides
Mechanism of Action Src-family kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Prostate cancer; Solid tumours
Discontinued Endometriosis; Inflammation

Most Recent Events

17 Jun 2024 Discontinued - Preclinical for Endometriosis in United Kingdom (SC)
17 Jun 2024 Discontinued for Inflammation in United Kingdom (unspecified route)
06 Aug 2023 ValiRx has a patent pending for VAL 301 in European Union, Russia and US (ValiRx website, August 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com